The Board announces that on 28 November 2025, the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun International entered into the Framework Tenancy Agreements in relation to the lease of the relevant Fosun Pharma Premises and Fosun International Premises in accordance with the terms thereof. Fosun International Premises: The properties owned by the Fosun International and/or its associates (excluding members of the Group unless such members are also Connected Subsidiaries of the Company under the Hong Kong Listing Rules, in which case such members shall be included) as set out in each of the relevant Tenancy and Property Service Agreements. Term: One year from 1 January 2026 to 31 December 2026 (both days inclusive).
Other: Subject to the requirement under the relevant laws and regulations and listing rules of Chinese mainland and Hong Kong, within the financial year (or relevant period) during the term of Lessee Framework Agreement, the parties agreed that the transactions contemplated thereunder shall be subject to the annual cap for such transactions as determined or approved by their respective board of directors or shareholders at their respective general meeting (as applicable). Lessor Framework Agreement: Parties: Parties: (1) the Company; and (2) Fosun International; Fosun Pharma: The properties owned by the Company and/or its subsidiaries as set out; Premises: in each of the relevant Tenancy and Property Service Agreements. Term: One year from 1 January 2026 to 31 December 2026 (both days inclusive).
Other: Subject to the requirement under the relevant laws and regulations and listing rules of Chinese mainland and Hong Kong, within the financial year (or relevant period) during the term of Lessor Framework Agreement, the parties agreed that the transactions contemplated thereunder shall be subject to the annual cap for such transactions as determined or approved by their respective board of directors or shareholders at their respective general meeting (as applicable). Fosun International Mutual Supply Framework Agreement: The Board announced that on 28 November 2025, the Company and Fosun International entered into the Fosun International Mutual Supply Framework Agreement in relation to the mutual supply between the Group and Fosun International and/or its associates, for a term of one year commencing from 1 January 2026 to 31 December 2026. Parties: (1) the Company; and (2) Fosun International Products and service provided by the Group to Fosun International and/or its associates: Under the Fosun International Mutual Supply Framework Agreement, the products and services to be provided by the Group to Fosun International and/or its associates from time to time during the term thereof mainly include the followings: (a) Products: medical products including medicine, diagnostics and medical devices; and (b) Services: (i) medical services; (ii) medical examination services such as body check and health risk assessment and other related services; (iii) diagnosis testing services; and (iv) pharmaceutical industry consulting services.
Term: One year from 1 January 2026 to 31 December 2026 (both days inclusive). Other: Subject to the requirement under the relevant laws and regulations and listing rules of Chinese mainland and Hong Kong, within the financial year (or relevant period) during the term of Fosun International Mutual Supply Framework Agreement, the parties agreed that the transactions contemplated thereunder shall be subject to the annual cap for such transactions as determined or approved by their respective board of directors or shareholders at their respective general meeting (as applicable).
